Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients

Prostate

Volumn 43, Issue 1, 2000, Pages 59-62

  Murphy, G P ^a   Tjoa, B A ^a   Simmons, S J ^a   Rogers, M K ^a   Kenny, G M ^a   Jarisch, J ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Dendritic cells; Prostate cancer; PSMA peptides

Indexed keywords

PEPTIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; BONE SCINTISCANNING; CLINICAL ARTICLE; DENDRITIC CELL; DOSE RESPONSE; FOLLOW UP; HUMAN; LEUKAPHERESIS; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0034106147     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000401)43:1<59::AID-PROS8>3.0.CO;2-D     Document Type: Article

References (8)

1. Middleton RG, Smith JA Jr, Melzer BB, Hamilton PE. Patient survival and local recurrence following radical prostatectomy for prostatic carcinoma. J Urol 1986;136:422-424.
2. Hanks GE, Krall JM, Hanlon AL, Ashell SO, Pilepich MV, Owen JB. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 1994;28:39-45.
3. Jones GW, Mettlin C, Murphy GP, Guinan P, Herr HW, Hussey DH, Chmiel JS, Fremgen AM, Clive RP, Zuber-Ocwieja KE, Winchester DP. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg 1995;180:545-554.
4. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller MI, Boynton AL, Murphy GP. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
5. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38:73-78.
6. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54-59.
7. Simmons SJ, Tjoa BA, Rogers MK, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999;39:291-297.
8. Tjoa BA, Simmons SJ, Elgamal A, Rogers MK, Kenny GM, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999;40:125-129.